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Available online 9 September 2014Evidence continues to support a relationship between fasting
and non-fasting plasma triglycerides (TG) and coronary heart dis-
ease (CHD), but is it the triglycerides that are causative or is it the
lipid/lipoprotein company they keep, e.g. reductions in HDL
cholesterol [1]. And in patients with type 2 diabetes, a population
wherein hypertriglyceridemia is more common [2,3], plasma TG
appear to be an important contributor to CVD risk [4,5]. This as-
sociation could very well be causal; the major TG-containing lipo-
protein in fasted subjects is very low density lipoproteins (VLDL)
and to a lesser extent intermediate density lipoproteins (IDL)
(d > 1.006 but <1.019), both apoB-100 containing. In non-fasted
subjects VLDL in addition to chylomicron and VLDL remnants
contribute to the pool. Often ignored is the fact that remnants are
by-products of TG-rich lipoprotein metabolism by lipoprotein
lipase (LPL), not the intermediate density particles secreted in
fasted subjects [6]. Moreover, the theoretical added value of non-
fasting TG is the atherogenicity of chylomicron remnants, identi-
ﬁed by their content of apoB-48 [7]; yet VLDL remnants are indis-
tinguishable from IDL in fasted subjects. So then why would levels
of VLDL cholesterol (VLDL-C) solve this quandary? Perhaps it's all
cholesterol not triglycerides, and this is examined in the Penn
Diabetes Heart Study (PDHS) cohort and published by Prenner et al.
in a previous issue of Atherosclerosis [22].
Plasma apo B-100 represents pro-atherogenic particles, and
noteworthy in the Prenner et al. paper is the substantial weakening
of the relationship between VLDL-C and coronary arteryDOI of original article: http://dx.doi.org/10.1016/j.atherosclerosis.2014.07.008.
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ple, p ¼ 0.005) when apo B was included in Model 4 (p ¼ 0.03).
Because IDL and VLDL remnants would be expected to contribute a
relatively small amount of apo B-100 [8], it must be assumed that
this reduction in the strength of association of VLDL-C and CAC
must be from LDL; unfortunately LDL-C was not co-varied in a
similar manner.
Another inquiry relates to deﬁning a positive CAC score as a level
>0. Moreover, a CAC score distribution is not provided and the
reproducibility of the method is not stated. Thus, a comparison of
two scans may have revealed one at 0 and another >0, e.g. 8. Ac-
cording to the method by which scores were calculated (Agatston),
the speciﬁcity of a CAC score of 1 was reported as 61% but increased
to 87% at 25 [9]. Moreover, the validation studies of Hokanson et al.
[10] indicate that a cut-point of 6.25 provided >99% certainty that
the CAC score is not 0. With values <6.25 one cannot reliably state
the CAC score is different than 0. In addition, it has also been shown
that a cut-point of 6.25 to deﬁne progression of CAC is the best
predictor of future mortality compared to other methods of
assessing CAC [11]. Perhaps the unacceptably low threshold for
positivity used in PDHS could have inﬂuenced the VLDL-C/CAC
results?
The stronger relationship between VLDL-C and CAC in women
than men extends previous observations that suggested a stronger
association of hypertriglyceridemia with coronary heart disease
(CHD) risk in women than men. In the 1980s data from Framing-
ham demonstrated a more robust relationship between fasting
plasma TG with cardiovascular disease (CVD) events in women
than men [12]. And, more recent analyses have conﬁrmed a
stronger relationship of both fasting and non-fasting plasma TG
with CVD in women than men [13]. However, despite the conve-
nience of non-fasting vs. fasting plasma TG and a similar if not
better CVD risk prediction of non-fasting than fasting values [14],
the most recent ACC/AHA Cholesterol Guideline is based on lipids
measured in fasted not non-fasted subjects [15,16].
An expected relationship between plasma VLDL-C and TG was
found (r ¼ 0.88, P < 0.0001), yet using Akaike information criteria
and Bayesian information criteria the authors provide evidence tor the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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when all other confounders and covariates were held equal.
Important to note is that a plasma TG of 150 mg/dL has been
routinely used to estimate levels of VLDL-C in fasted subjects, and
consequently to calculate LDL-C [17]. Prenner et al. then used
plasma TG < 150 vs. >150 mg/dL to demonstrate a relationship to
CAC, an effect that was weaker than that seen for VLDL-C (Ref).
Perhaps a level of <200 vs. >200 mg/dL would have added addi-
tional insight into some of the ﬁbrate trials wherein post hoc an-
alyses suggested a ﬁbrate beneﬁt with fasting TG concentrations
>~200mg/dL with or without statin therapy [18e20]. It would have
also been interesting to compare the newly developed ACC/AHA
risk estimator [21] to the Framingham Risk Score in this cohort.
Moreover, the statin and other lipid altering drug effect is note-
worthy e fewer subjects were treated as VLDL-C increased and the
relationship between VLDL-C and CAC became non-signiﬁcant in
both men and women with additional modeling.
To summarize, the PDHS is a large cohort of patients with type 2
diabetes and the data of Prenner et al. provide uswith evidence that
an infrequently examined biomarker related to risk of atheroscle-
rosis, VLDL-C. Plasma concentrations of VLDL-C are relatively easy
to quantify (b-quantiﬁcation) and although CAC is an effective non-
invasive method to evaluate the presence of coronary heart disease
and plaque burden, CAC falls far short of examining the impact of
such a biomarker on CVD events. Validation is now needed as are
additional mechanistic studies as to how TG-rich lipoproteins and/
or their composition cause or relate to ASCVD risk in patients with
type 2 diabetes and beyond.
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